Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 12/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.51 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21882985 | 1.00 | DNPH1 (0.53) | DNPH1P2RX1P2RX3P2RX4RXFP1 | |
| SCHEMBL21882958 | 0.86 | P2RX3 (0.54) | DNPH1P2RX1P2RX3P2RX4RXFP1 | |
| SCHEMBL30394191 | 0.86 | P2RX3 (0.54) | DNPH1P2RX1P2RX3P2RX4RXFP1 | |
| SCHEMBL23915001 | 0.86 | P2RX3 (0.54) | DNPH1P2RX1P2RX3P2RX4RXFP1 | |
| SCHEMBL30394237 | 0.85 | DNPH1 (0.73) | DNPH1 | |
| SCHEMBL21882959 | 0.84 | NT5E (0.52) | P2RX1P2RX3P2RX4RXFP1PI4KA | |
| SCHEMBL23915675 | 0.84 | NT5E (0.52) | P2RX1P2RX3P2RX4RXFP1PI4KA | |
| SCHEMBL30395399 | 0.84 | NT5E (0.52) | P2RX1P2RX3P2RX4RXFP1PI4KA | |
| SCHEMBL21883338 | 0.83 | P2RX3 (0.51) | DNPH1P2RX1P2RX3P2RX4RXFP1 | |
| SCHEMBL30394247 | 0.83 | P2RX3 (0.51) | DNPH1P2RX1P2RX3P2RX4RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | DNPH1 1090/4885P2RX1 20/4885P2RX3 14/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | DNPH1 297/4885P2RX1 39/4885P2RX3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.